Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

ClinicalTrials.gov ID: NCT01017731

Public ClinicalTrials.gov record NCT01017731. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.

Study identification

NCT ID
NCT01017731
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
68 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2009 (Type not available)
Primary completion
Apr 2010 (Actual)
Completion
May 2014 (Actual)
Last update posted
Jun 10, 2015

2009 – 2014

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
ImClone Investigational Site Atlanta Georgia 30322 —
ImClone Investigational Site Metairie Louisiana 70006 —
ImClone Investigational Site Ann Arbor Michigan 48109 —
ImClone Investigational Site Philadelphia Pennsylvania 19111 —
ImClone Investigational Site Providence Rhode Island 02903 —
ImClone Investigational Site Houston Texas 77024 —
ImClone Investigational Site Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01017731, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2015 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01017731 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →